Extracted from this filing and checked against the source text.
Listing & Compliance Notices
SEC 8-K Item 3.01
confidence 0.9
SOLIGENIX, INC. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).
- Exchange
- nasdaq
- Notice
- deficiency notice
- Deficiency
- stockholders equity
- Rules
- 5550(b)(1)
Exact text from the filing
(the “Stockholders’ Equity Requirement”). In the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2022, the Company reported stockholders’ equity of $1,032,002, which is below the Stockholders’ Equity Requirement for continued listing. Additionally, as of the date of this report, the Company does not meet either of the alternative Nasdaq
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
SOLIGENIX, INC. shareholders rejected proposal to approve an amendment to the Company’s Second Amended and Restated Certificate of Incorporation, as amended, to increase the number of authorized shares of common stock from 75,000,000 to 125,000,000 at the 2022-09-22 meeting.
- Proposal
- charter amendment
- Outcome
- failed
- Meeting
- 2022-09-22
Exact text from the filing
Despite support for Proposal 2 exceeding 80% of the votes cast on the proposal, Proposal 2 did not receive the affirmative vote of holders of more than 50% of the Company’s issued and outstanding shares of Common Stock and, therefore, was not approved. A large proportion of the stockholders holding shares through banks, brokers or other nominees could not be identified or were unresponsive to the Company’s outreach in urging them to vote their shares. The votes were as follows: For Against Abstain 19,250,158 4,741,417 409,816 There were no broker non-votes on this proposal.
View on SEC.gov